bioRxiv · 10.1101/2020.12.09.415927
Cross-Platform Omics Prediction procedure enables precision medicine in patients with stage-III melanoma
Abstract
There is no consensus methodology that can account for the variation in omics signatures when they are acquired across different platforms and times. This poses a significant barrier to the implementation of valuable biomarkers into clinical practice. We present a novel procedure (Cross-Platform Omics Prediction) that accounts for these variations and demonstrate its utility in three risk models for different diseases that is suitable for prospective and multi-centre clinical implementation.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Wang, K. Y., Pupo, G. M., Tembe, V., Patrick, E., Strbenac, D., Schramm, S.-J., Thompson, J. F., Scolyer, R. A., Mueller, S., Tarr, G., Mann, G. J., Yang, J. Y.. 2020-12-09. Cross-Platform Omics Prediction procedure enables precision medicine in patients with stage-III melanoma. https://doi.org/10.1101/2020.12.09.415927
Cite the original work for its findings. Save a collection to share your selection of sources.